Cargando…
Are there any differences in the regulations of personalized medicine among the USA, EU and Japan?
Autores principales: | Shimazawa, Rumiko, Ikeda, Masayuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Science Inc
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3635607/ https://www.ncbi.nlm.nih.gov/pubmed/22978372 http://dx.doi.org/10.1111/j.1365-2125.2012.04462.x |
Ejemplares similares
-
Approval status and evidence for WHO essential medicines for children in the United States, United Kingdom, and Japan: a cross-sectional study
por: Shimazawa, Rumiko, et al.
Publicado: (2017) -
Challenges to hemoglobin A1c as a therapeutic target for type 2 diabetes mellitus
por: Ikeda, Masayuki, et al.
Publicado: (2019) -
Imbalance in glycemic control between the treatment and placebo groups in cardiovascular outcome trials in type 2 diabetes
por: Shimazawa, Rumiko, et al.
Publicado: (2019) -
Potential adverse events in Japanese women who received tozinameran (BNT162b2, Pfizer-BioNTech)
por: Shimazawa, Rumiko, et al.
Publicado: (2021) -
Natural language processing‐based assessment of consistency in summaries of product characteristics of generic antimicrobials
por: Shimazawa, Rumiko, et al.
Publicado: (2018)